Skip to main content
. Author manuscript; available in PMC: 2022 May 16.
Published in final edited form as: Lancet Infect Dis. 2015 Dec 21;16(3):321–330. doi: 10.1016/S1473-3099(15)00488-0

Table 1:

Participant characteristics

mIPV2HD group (n=117) IPV group (n=116)
Age (weeks)  6·1 (0·84)  6·1 (0·91)
Sex
 Male   58 (50%)   63 (54%)
 Female   59 (50%)   53 (46%)
Race
 White  2 (2%)     1 (1%)
 Black or African-American  5 (4%)   10 (9%)
 Asian  0     0
 Hispanic 107 (91%) 102 (88%)
 Other  3 (3%)  3 (3%)
Breastfed
 Yes 114 (97%) 112 (97%)
 No  3 (3%)  4 (3%)
Attending a day-care centre
 Yes  1 (1%)  0
 No 116 (99%) 116 (100%)

Data are mean (SD) or n (%). mIPV2HD=monovalent inactivated poliovirus vaccine, type 2, high dose. IPV=trivalent inactivated poliovirus vaccine.